What is involved?
This research study will continue to evaluate the side effects of 131I-MIBG when treating children and adults with neuroblastoma.
- The 131I-MIBG compound is intended to work by selectively delivering the radioactive iodine to the cancer cells, which is then intended to result in their destruction.
- One treatment cycle of 131I-MIBG therapy is 7 to 9 weeks long. The patient will be evaluated to receive additional 131I-MIBG therapy at the end of each cycle. If they qualify and their blood counts are good, it is possible that they could receive a total of three treatment cycles, for a total of 21 to 27 weeks. Hospitalization is required for approximately 3-5 days after each dose.